comparemela.com

Latest Breaking News On - Oncternal therapeutics company profile - Page 1 : comparemela.com

StockNews com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $28.00 to $19.00 and set a […]

Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews com

Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews com

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the stock. Separately, HC Wainwright cut their price target on Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a research […]

Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note released on Wednesday. The firm issued a hold rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a report […]

Oncternal Therapeutics, Inc (NASDAQ:ONCT) Given Consensus Recommendation of Hold by Analysts

Shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Free Report) have been given a consensus recommendation of “Hold” by the six ratings firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.